Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CLAUDIA MILY ESPINOSA

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1093840522
CMS profile
564928
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$15,390.67

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $14,425.00 3
Travel and Lodging $695.43 5
Food and Beverage $270.24 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $12,880.67 12
Gilead Sciences, Inc. $2,510.00 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CLAUDIA MILY ESPINOSA

NPI 1093840522 · CMS profile ID 564928

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093840522?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CLAUDIA MILY ESPINOSA, NPI 1093840522, CMS profile ID 564928. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093840522?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CLAUDIA MILY ESPINOSA, NPI 1093840522, CMS profile ID 564928. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093840522?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CLAUDIA MILY ESPINOSA, NPI 1093840522, CMS profile ID 564928, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093840522?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $15,390.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $2,510.0012/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035502181 CMS
SANOFI PASTEUR INC. $74.4204/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213103 CMS
SANOFI PASTEUR INC. $107.9904/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213105 CMS
SANOFI PASTEUR INC. $6,860.0004/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213107 CMS
SANOFI PASTEUR INC. $50.0001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147433 CMS
SANOFI PASTEUR INC. $35.0001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147447 CMS
SANOFI PASTEUR INC. $50.0001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147461 CMS
SANOFI PASTEUR INC. $5,055.0001/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147471 CMS
SANOFI PASTEUR INC. $25.2401/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147483 CMS
SANOFI PASTEUR INC. $45.3301/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147497 CMS
SANOFI PASTEUR INC. $350.6901/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147393 CMS
SANOFI PASTEUR INC. $117.0001/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147407 CMS
SANOFI PASTEUR INC. $110.0001/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044147421 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,622.03 2
PY2020 $9,682.00 6
PY2021 $2,236.13 3
PY2022 $18,359.74 38
PY2023 $15,390.67 13
PY2024 $4,135.77 13
PY2025 $18,851.48 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $113,811.25 17
PY2024 Principal investigator $195,398.86 23
PY2023 Principal investigator $109,978.41 10
PY2022 Principal investigator $179,669.92 9
PY2021 Principal investigator $9,660.54 2
PY2020 Principal investigator $15,832.98 4
PY2019 Principal investigator $84,083.43 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $13,074.39 12/03/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670105433
Principal investigator 1 Janssen Research & Development, LLC $8,694.24 11/27/2019 Non-covered Recipient Entity
Univ Of Louisville Clinic Trials Unit
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection No dispute reported 06/30/2026 654264375
Principal investigator 1 Allergan Inc. $1,985.00 11/26/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670103637
Principal investigator 1 Allergan Inc. $2,646.00 11/26/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670103859
Principal investigator 1 Allergan Inc. $2,299.00 11/26/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670103865
Principal investigator 1 Allergan Inc. $428.40 11/26/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670103991
Principal investigator 1 Allergan Inc. $1,323.00 11/26/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670104137
Principal investigator 1 Allergan Inc. $7,424.00 11/26/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670104285
Principal investigator 1 Gilead Sciences, Inc. $630.00 08/26/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 676398425
Principal investigator 1 Gilead Sciences, Inc. $1,396.00 07/17/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 676398419
Principal investigator 1 Melinta Therapeutics, Inc. $483.00 07/10/2019 Non-covered Recipient Entity
University of Louisville
TMC-ORI-10-01 No dispute reported 06/30/2026 705353483
Principal investigator 1 Melinta Therapeutics, Inc. $750.00 06/27/2019 Non-covered Recipient Entity
Univeristy of Louisville Research Foundation
TMC-ORI-10-01 No dispute reported 06/30/2026 705353479
Principal investigator 1 Gilead Sciences, Inc. $2,645.00 06/19/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 676398411
Principal investigator 1 Melinta Therapeutics, Inc. $750.00 06/12/2019 Non-covered Recipient Entity
Univeristy of Louisville Research Foundation
TMC-ORI-10-01 No dispute reported 06/30/2026 705353471
Principal investigator 1 Melinta Therapeutics, Inc. $1,088.00 06/12/2019 Non-covered Recipient Entity
University of Louisville
TMC-ORI-10-01 No dispute reported 06/30/2026 705353475
Principal investigator 1 Gilead Sciences, Inc. $2,390.00 05/22/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 676398407
Principal investigator 1 Janssen Research & Development, LLC $2,700.00 05/13/2019 Non-covered Recipient Entity
Univ Of Louisville Rsrch Fndtn
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection No dispute reported 06/30/2026 654264377
Principal investigator 1 Melinta Therapeutics, Inc. $4,828.00 05/10/2019 Non-covered Recipient Entity
University of Louisville
TMC-ORI-10-01 No dispute reported 06/30/2026 705353463
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 05/09/2019 Non-covered Recipient Entity
KOSAIR CHARITIES PEDIATRIC CLINICAL RESEARCH UNIT
A Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old No dispute reported 06/30/2026 691333013
Principal investigator 1 Gilead Sciences, Inc. $1,080.00 05/01/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 676398405
Principal investigator 1 Gilead Sciences, Inc. $4,824.00 04/17/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 676398401
Principal investigator 1 Merck Sharp & Dohme Corporation $5,879.00 04/09/2019 Non-covered Recipient Entity
KOSAIR CHARITIES PEDIATRIC CLINICAL RESEARCH UNIT
A Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old No dispute reported 06/30/2026 691324643
Principal investigator 1 Allergan Inc. $7,424.00 02/28/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670028291
Principal investigator 1 Allergan Inc. $662.00 02/28/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDA
PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTION No dispute reported 06/30/2026 670028337
Principal investigator 1 Gilead Sciences, Inc. $1,396.00 02/20/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 676398397
Principal investigator 1 Merck Sharp & Dohme Corporation $1,089.90 02/07/2019 Non-covered Recipient Entity
KOSAIR CHARITIES PEDIATRIC CLINICAL RESEARCH UNIT
A Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old No dispute reported 06/30/2026 691323387
Principal investigator 1 Gilead Sciences, Inc. $1,332.00 01/28/2019 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 676398391
Principal investigator 1 Merck Sharp & Dohme Corporation $2,362.50 01/17/2019 Non-covered Recipient Entity
KOSAIR CHARITIES PEDIATRIC CLINICAL RESEARCH UNIT
A Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old No dispute reported 06/30/2026 691311083